Investor spotlight: M Ventures

Date

25.04.2019 17:00 - 18:30

Location

Room SV1717, SV building, EPFL, Lausanne

Register

Follow this Link

This Life Science event will have Dr. Jasper Bos, Senior Vice President and Managing Director of the M Ventures Healthcare fund, presenting an overview of the fund, its investment strategy and primary areas of interest as well as some interesting case studies. 

A special example of the M Ventures investment strategy is Prexton Therapeutics, a Swiss-based biopharmaceutical company launched in 2012. We are also delighted that Dr. Francois Conquet, CEO and founder of Prexton, talks about the exciting story of the company’s powerful discovery platform used to target specific novel compounds focused on the treatment of Parkinson’s disease. Francois will also share his “lessons learned along the way”.
 
Overview M Ventures
Merck Ventures is the strategic, corporate venture capital arm of Merck KGaA. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From their headquarters in Amsterdam and offices in the US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs. The fund takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
 
Please join us at this event on April 25th 2019, 16:30 to 18:30, at Room SV1717, SV building, EPFL, Lausanne.

rss